Recent Investment Analysts’ Ratings Changes for Checkpoint Therapeutics (CKPT)

Checkpoint Therapeutics (NASDAQ: CKPT) recently received a number of ratings updates from brokerages and research firms:

  • 1/22/2018 – Checkpoint Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “
  • 1/19/2018 – Checkpoint Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.50 price target on the stock. According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “
  • 1/10/2018 – Checkpoint Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “
  • 1/4/2018 – Checkpoint Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.00 price target on the stock. According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “
  • 1/3/2018 – Checkpoint Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “
  • 12/8/2017 – Checkpoint Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $11.00 price target on the stock.

Shares of Checkpoint Therapeutics Inc (NASDAQ:CKPT) opened at $4.69 on Tuesday. Checkpoint Therapeutics Inc has a 1-year low of $3.20 and a 1-year high of $15.00. The firm has a market capitalization of $119.88 and a price-to-earnings ratio of -4.19.

Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.

Receive News & Ratings for Checkpoint Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply